NCT02985749View on ClinicalTrials.gov

A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 9, 2017

Primary Completion Date

January 9, 2019

Study Completion Date

January 9, 2019

Conditions
Autism Spectrum DisorderPervasive Developmental DisorderASDPDD
Interventions
DRUG

Intranasal Oxytocin

This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).

Trial Locations (1)

02114

Massachusetts General Hospital, Cambridge

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT02985749 - A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder | Biotech Hunter | Biotech Hunter